Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964560 | 0.94 | BTK (0.37) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL574102 | 0.92 | BTK (0.36) | CHRM2CHRM1CHRM3HSD11B1NFKB1 | |
| SCHEMBL871258 | 0.90 | GAA (0.37) | CHRM2CHRM1CHRM3HSD11B1NFKB1 | |
| SCHEMBL6262075 | 0.89 | BTK (0.39) | HSD11B1BTK | |
| SCHEMBL6424027 | 0.88 | PLG (0.38) | NFKB1NFKB2RELAHDAC6HDAC1 | |
| SCHEMBL15021681 | 0.87 | SLC6A4 (0.32) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1783229 | 0.87 | USP2 (0.39) | CHRM2CHRM1CHRM3HSD11B1GPR119 | |
| SCHEMBL27821583 | 0.86 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1 | |
| SCHEMBL1128903 | 0.83 | HPGD (0.50) | HSD11B1GPR119HPGD | |
| SCHEMBL2595519 | 0.83 | ALDH1A1 (0.45) | HSD11B1NFKB1NFKB2RELAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105503647-A | Preparation method of cyclopropylhydrazine hydrochloride | SUZHOU HIGHFINE BIOTECH CO LTD | 2016-04-20 | — | — | CN | claimed |
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | NEWAVE PHARMACEUTICAL INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11299493-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3952875-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | NEWAVE PHARMACEUTICAL INC. | 2021-03-04 | — | — | US | disclosed |
| CN-101253155-A | 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1 | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007025892-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1-INHIBITOR-DIABETES-TYPE 2-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | BANNER BRUCE L | 2007-03-01 | — | — | US | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299493-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, NME1 | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4880/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4880/4885 |
| US-20070049632-A1 | Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD17B1, HSD17B2, HSD3B2 | CHRM2 4488/4885CHRM1 4658/4885CHRM3 4480/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | CHRM2 1100/4885CHRM1 691/4885CHRM3 547/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | CHRM2 4875/4885CHRM1 4854/4885CHRM3 4880/4885 |
| US-20210061807-A1 | 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDINE-3-ONE COMPOUNDS AS INHIBITORS OF WEE-1 KINASE | WEE1, WEE2, PEAK1 | CHRM2 3739/4885CHRM1 2827/4885CHRM3 4380/4885 |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | WEE1, WEE2, PHKG1 | CHRM2 3906/4885CHRM1 3173/4885CHRM3 4468/4885 |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | CHRM2 3607/4885CHRM1 3945/4885CHRM3 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.